{"entity":{"id":"infinitopes","kind":"company","name":"Infinitopes","aka":[],"tldr":"Infinitopes is an Oxford company making an off-the-shelf cancer vaccine meant to train the immune system to stop oesophageal cancer coming back after surgery. Its vaccine, ITOP1, was preparing for its first placebo-controlled human trial in 2026.","summary":"Infinitopes was spun out of the University of Oxford in 2021 and is based at the BioEscalator in Oxford, with support from Cancer Research UK. Its Precision Immunomics platform measures the tumour immunopeptidome directly and uses machine learning trained on patient samples to choose tumour-specific targets, which are delivered with engineered viral vectors intended to give durable CD8 T-cell responses from a prime-and-boost schedule.\n\nIn April 2024 it announced a GBP 12.8 million seed round led by Octopus Ventures with Cancer Research Horizons, the Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital and Manta Ray among others. In January 2026 a second close co-led by Octopus Ventures and Amplify Bio brought the seed to USD 35.1 million, to fund VISTA, a first-in-human, double-blind, randomised, placebo-controlled phase 1/2a study of ITOP1 given around chemotherapy and surgery to reduce recurrence of oesophageal cancer after resection.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.infinitopes.com/"},{"label":"Seed financing, April 2024","url":"https://www.biospace.com/integrated-cancer-biotech-infinitopes-secures-12-8m-seed-financing-to-enhance-its-precision-immunomics-antigen-discovery-technologies-to-target-five-more-cancers"},{"label":"European Biotechnology: USD 35 million seed, January 2026","url":"https://european-biotechnology.com/latest-news/oxford-based-cancer-vaccine-company-infinitopes-closes-35-million-seed-round/"}],"tags":[],"related":[],"cancers":["esophageal"],"sections":["immunotherapy"],"technologies":["shared-antigen-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The company site states that a seed round closed in December 2023; it was first announced in April 2024. Trial timing on the company site is inconsistent (one passage says the trial began in 2024, the timeline says enrolment in the second half of 2025), so no start date is recorded."],"hq":"Oxford","country":"GB","companyType":"biotech","website":"https://www.infinitopes.com/","founded":2021,"stage":"startup","investors":["cancer-research-horizons"],"funding":[{"round":"Seed","year":2024,"source":"https://www.biospace.com/integrated-cancer-biotech-infinitopes-secures-12-8m-seed-financing-to-enhance-its-precision-immunomics-antigen-discovery-technologies-to-target-five-more-cancers","note":"GBP 12.8 million seed led by Octopus Ventures, announced April 2024; no USD figure given"},{"round":"Seed (second close)","year":2026,"amountUsd":15400000,"source":"https://european-biotechnology.com/latest-news/oxford-based-cancer-vaccine-company-infinitopes-closes-35-million-seed-round/","note":"Second close co-led by Octopus Ventures and Amplify Bio, bringing total seed financing to USD 35.1 million"}]},"route":"/companies/infinitopes/","neighbours":{"cancer":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}],"company":[{"id":"cancer-research-horizons","kind":"company","name":"Cancer Research Horizons","route":"/companies/cancer-research-horizons/"}]}}